CA2600946A1 - Compositions and methods for inhibiting g protein signaling - Google Patents

Compositions and methods for inhibiting g protein signaling Download PDF

Info

Publication number
CA2600946A1
CA2600946A1 CA002600946A CA2600946A CA2600946A1 CA 2600946 A1 CA2600946 A1 CA 2600946A1 CA 002600946 A CA002600946 A CA 002600946A CA 2600946 A CA2600946 A CA 2600946A CA 2600946 A1 CA2600946 A1 CA 2600946A1
Authority
CA
Canada
Prior art keywords
protein
sigk
binding
subunit
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002600946A
Other languages
English (en)
French (fr)
Inventor
Alan V. Smrcka
Jose Font
Tabetha Bonacci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2600946A1 publication Critical patent/CA2600946A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
CA002600946A 2005-03-07 2006-03-07 Compositions and methods for inhibiting g protein signaling Abandoned CA2600946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65926705P 2005-03-07 2005-03-07
US60/659,267 2005-03-07
PCT/US2006/008031 WO2006096690A2 (en) 2005-03-07 2006-03-07 Compositions and methods for inhibiting g protein signaling

Publications (1)

Publication Number Publication Date
CA2600946A1 true CA2600946A1 (en) 2006-09-14

Family

ID=36953955

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002600946A Abandoned CA2600946A1 (en) 2005-03-07 2006-03-07 Compositions and methods for inhibiting g protein signaling

Country Status (7)

Country Link
US (2) US20090221691A1 (enExample)
EP (1) EP1868634A4 (enExample)
JP (1) JP2008537481A (enExample)
CN (1) CN101171022A (enExample)
AU (1) AU2006220652A1 (enExample)
CA (1) CA2600946A1 (enExample)
WO (1) WO2006096690A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523092C (zh) * 2005-05-16 2009-08-05 徐州开达精细化工有限公司 蒽醌型还原染料16,17-二溴紫蒽酮和16,17-二(1’-亚胺基蒽醌基)紫蒽酮及其制备方法
EP2147310A4 (en) * 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
WO2011040564A1 (ja) * 2009-09-30 2011-04-07 千寿製薬株式会社 特定のペプチド化合物を有効成分として含む眼科用剤
CN105802970A (zh) * 2016-05-30 2016-07-27 东北师范大学 靶向沉默Gβ1的shRNA
US10436795B2 (en) * 2016-09-16 2019-10-08 Institute For Cancer Research Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein
CN106908610B (zh) * 2017-03-13 2018-11-02 绍兴康知生物科技有限公司 一种基于受体配体结合技术筛查吸食吗啡的试剂、制备方法及应用
CN108802366B (zh) * 2017-05-04 2020-01-21 中国科学院微生物研究所 一种检测待测样本中目标蛋白的含量的方法
CN115368386A (zh) * 2022-08-09 2022-11-22 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种防治骨性关节炎的小分子化合物及其用途
WO2025157155A1 (zh) * 2024-01-23 2025-07-31 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0548165T3 (da) * 1990-09-13 2001-07-16 Univ Duke Ekspression af G-proteinkoblede receptorer i gær
CA2219958A1 (en) * 1998-01-07 1999-07-07 Ekkehard Leberer The g-protein .beta.subunit interaction domain of ste20p/pak family of protein kinases and uses thereof in bioassays
US7189519B2 (en) * 1998-08-10 2007-03-13 Stc.Unm Bead-based detection of ligand-GPCR-G protein complexes
PT1139793E (pt) * 1998-12-23 2010-01-19 Sinai School Medicine Inibidores da resposta ao sabor amargo
WO2000045179A2 (en) * 1999-01-27 2000-08-03 The Regents Of The University Of California Screening for modulators of g-protein subunit beta 3
CA2385460A1 (en) * 1999-09-21 2001-03-29 Forsyth Dental Infirmary For Children Rgs10b, a g-protein regulator expressed in osteoclasts
WO2003062393A2 (en) * 2002-01-22 2003-07-31 Bristol-Myers Squibb Company G protein-coupled receptor variants
US20040121330A1 (en) * 2002-12-18 2004-06-24 Feder John N. Novel human G-protein coupled receptor, HGPRBMY4, and methods of use thereof
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity

Also Published As

Publication number Publication date
US20090221691A1 (en) 2009-09-03
US20130116313A1 (en) 2013-05-09
CN101171022A (zh) 2008-04-30
WO2006096690A3 (en) 2007-11-08
EP1868634A2 (en) 2007-12-26
AU2006220652A1 (en) 2006-09-14
EP1868634A4 (en) 2010-10-20
JP2008537481A (ja) 2008-09-18
US8748480B2 (en) 2014-06-10
WO2006096690A2 (en) 2006-09-14

Similar Documents

Publication Publication Date Title
US8748480B2 (en) Methods for treating opioid tolerance
US6207397B1 (en) In vitro fluorescence polarization assay
CN101490557B (zh) 用于鉴定与zap-70相互作用的分子和纯化zap-70的方法
US8691947B2 (en) Materials related to sodium/potassium adenosine triphosphatase and Src
KR101804285B1 (ko) TCTP 이량체형 IgE-의존성 히스타민 방출인자와 이의 수용체간의 결합을 억제하는 TCTP 유래 C-말단 도메인 및 이의 용도
JP4371821B2 (ja) Ｓ１００−ｐ５３タンパク質間相互作用のインヒビター、およびそれを使用して癌を阻害する方法
Khrapunovich-Baine et al. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization
AU2807697A (en) In vitro fluorescence polarization assay
Wang et al. A novel peptide exerts potent immunosuppression by blocking the two-site interaction of NFAT with calcineurin
Faitar et al. EVI5 is a novel centrosomal protein that binds to α-and γ-tubulin
Williams et al. Identification of a novel cyclin-like protein in human tumor cells.
CN105377298A (zh) 一种增加脊柱侧凸受试者的细胞中的gipcr信号传导作用的方法
Thibodeau et al. Calmodulin binds and modulates K+-dependent Na+/Ca2+-exchanger isoform 4, NCKX4
Bae et al. Interaction of T-type calcium channel CaV3. 3 with the β-subunit
US8927297B2 (en) Methods to measure dissociation rates for ligands that form reversible covalent bonds
CA2405311A1 (en) Multiprotein-complexes comprising a nmda receptor and uses thereof
US20060160201A1 (en) Three-dimensional structures of HDAC9 and Cabin1 and compound structures and methods related thereto
EP1403282A1 (en) Protein complexes of the Tumor necrosis factor-alpha (TNF-alpha) signalling pathway
Topacio et al. Identification and inhibition of the Cyclin D Rb-docking interface that drives cell division
US7122655B2 (en) Compositions involving M-RIP, and related methods for screening for anti-hypertensive agents, and uses thereof
US20120226021A1 (en) Co-Crystallization of ERR-alpha with a Ligand that Forms a Reversible Covalent Bond
TEP Human Kelch-like protein 20 (KLHL20)
WO2005009469A1 (ja) 新規血糖調節薬及びそのスクリーニング方法
Bonacci Molecular mechanisms defining G-protein βγ subunit recognition and regulation of target molecules: Potential of Gβγ as a pharmacological target
McCullar Regulation of phospholipase C-beta isozymes by calmodulin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150309